TCL Archive O’Shaughnessy, Burris To Present for Genentech At FDA Hearing At June 28-29 June 10, 2011
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive In Brief: Weissman Heads DCBD Board; Extra Money For Grants Lifts Funding Level To 35% October 14, 1977
